1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Screening Improvement Program Award is sponsored by Cystic Fibrosis Foundation. This Request for Applications (RFA) focuses on improving equity and expediting the early diagnosis of cystic fibrosis through uniformly accelerated newborn screening (NBS). It prioritizes addressing the special needs of diverse populations of U.S. infants.
Projects should aim for quality improvement in NBS systems, including education, screening, follow-up, diagnosis, medical management, and quality assurance.
Get alerted about grants like this
Get emailed when new opportunities from “Cystic Fibrosis Foundation” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
This request for applications (RFA) is focused on improving equity and expediting the early diagnosis of cystic fibrosis through uniformly accelerated newborn screening (NBS) that includes as a priority addressing the special needs of the diverse populations of U.S. infants. However, this RFA is not intended to support projects devoted to clinical trials/interventions.
NBS programs are organized as population-based public health services applying preventive medicine principles in defined regions to reduce morbidity and mortality from genetic disorders by pre-symptomatic detection of risk. The programs use dried blood specimens from newborns analyzed in central laboratories that are linked to clinical follow-up programs for diagnosis and rapid institution of specialized therapies.
The organization of NBS programs features a system of care that includes education, the screening test(s) per se, follow-up, diagnosis, evaluation/management, and quality assurance. The timeliness of diagnosing CF through efficient, equitable NBS can be challenging.
Although guidelines for CF NBS published by the Clinical and Laboratory Standards Institute state that the goal is for all infants with CF to be diagnosed and integrated into clinical care systems at CF clinics by 2-3 weeks of age, data stored in the Cystic Fibrosis Foundation Patient Registry have revealed that many states are experiencing delays and not routinely diagnosing CF through NBS during the neonatal period, i.e., the first 28 days of life.
The Foundation believes that the timeliness aspect of this care delivery challenge, improvements in equity, and all the other components of the NBS system can be enhanced by quality improvement (QI) projects. Applicants are encouraged to refer to The Standards for Quality Improvement Reporting Excellence (SQUIRE 2. 0) revised publication guidelines to see what is required for work on QI-focused projects to be published.
Applicants must be U.S. citizens or U.S. permanent residents (prior to the time of application), actively engaged in CF newborn screening programs, and involved in the second, third, and fourth components listed below: 1. Education of professionals and parents 2. Screening, i.e., specimen collection, submission and testing 3.
Follow-up of abnormal and unsatisfactory test results 4. Confirmatory testing and diagnosis 5. Medical management and periodic outcome evaluation, including treatment monitoring 6.
System evaluation and quality assurance Applicant institutions should have a CF Foundation-accredited center or affiliate program. Applicants may request up to $75,000 per year for two years, plus an additional 12% of indirect costs may be requested per year. Refer to Section III of the Policies and Guidelines for further details regarding funding options.
## Policies and Guidelines Please review the 2026Policies and Guidelinesfor complete submission information. Full application:July 14, 2026 All applications must be submitted online at awards. cff.
orgby 5 p. m. ET on the aforementioned deadline.
Those who are interested in any funding programs offered by the CF Foundation may get further information or discuss the potential relevance of their studies or research by contacting the Grants and Contracts Management and Administration (GCMA) Office atgrants@cff. org. **Please Direct Inquiries to:** Cystic Fibrosis Foundation
According to the current listing, eligibility includes: U.S. citizens or U.S. permanent residents, actively engaged in CF newborn screening programs, and involved in various components of the NBS system (education, screening, follow-up, diagnosis, medical management, system evaluation, and quality assurance). Applicant institutions should have a CF Foundation-accredited center or affiliate program. Confirm the full requirements in the official notice before applying.
The current listing shows up to $75,000 per year for two years, plus an additional 12% of indirect costs. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Screening Improvement Program Award is funded by Cystic Fibrosis Foundation. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.